Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

Thierry Poynard; Julien Vergniol; Yen Ngo; Juliette Foucher; Mona Munteanu; Wassil Merrouche; Massimo Colombo; Vincent Thibault; Eugene Schiff; Clifford A. Brass; Janice K. Albrecht; Marika Rudler; Olivier Deckmyn; Pascal Lebray; Dominique Thabut; Vlad Ratziu; Victor De Ledinghen

doi:10.1016/j.jhep.2013.11.016

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

Thierry Poynard, Julien Vergniol, Yen Ngo, Juliette Foucher, Mona Munteanu, Wassil Merrouche, Massimo Colombo, Vincent Thibault, Eugene Schiff, Clifford A. Brass, Janice K. Albrecht, Marika Rudler, Olivier Deckmyn, Pascal Lebray, Dominique Thabut, Vlad Ratziu, Victor De Ledinghen

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called "EPIC", "Paris", and "Bordeaux" cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p

Original language	English
Pages (from-to)	706-714
Number of pages	9
Journal	Journal of Hepatology
Volume	60
Issue number	4
DOIs	https://doi.org/10.1016/j.jhep.2013.11.016
Publication status	Published - 2014

Keywords

Cirrhosis complications
Elastography
Fibrosis stages
FibroTest™
Hepatocellular carcinoma
Prognostic factors
Surrogate markers

ASJC Scopus subject areas

Hepatology
Medicine(all)

Access to Document

10.1016/j.jhep.2013.11.016

Fingerprint Dive into the research topics of 'Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)'. Together they form a unique fingerprint.

Cite this

Poynard, T., Vergniol, J., Ngo, Y., Foucher, J., Munteanu, M., Merrouche, W., Colombo, M., Thibault, V., Schiff, E., Brass, C. A., Albrecht, J. K., Rudler, M., Deckmyn, O., Lebray, P., Thabut, D., Ratziu, V., & De Ledinghen, V. (2014). Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). Journal of Hepatology, 60(4), 706-714. https://doi.org/10.1016/j.jhep.2013.11.016

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). / Poynard, Thierry; Vergniol, Julien; Ngo, Yen; Foucher, Juliette; Munteanu, Mona; Merrouche, Wassil; Colombo, Massimo; Thibault, Vincent; Schiff, Eugene; Brass, Clifford A.; Albrecht, Janice K.; Rudler, Marika; Deckmyn, Olivier; Lebray, Pascal; Thabut, Dominique; Ratziu, Vlad; De Ledinghen, Victor.

In: Journal of Hepatology, Vol. 60, No. 4, 2014, p. 706-714.

Research output: Contribution to journal › Article › peer-review

Poynard, T, Vergniol, J, Ngo, Y, Foucher, J, Munteanu, M, Merrouche, W, Colombo, M, Thibault, V, Schiff, E, Brass, CA, Albrecht, JK, Rudler, M, Deckmyn, O, Lebray, P, Thabut, D, Ratziu, V & De Ledinghen, V 2014, 'Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)', Journal of Hepatology, vol. 60, no. 4, pp. 706-714. https://doi.org/10.1016/j.jhep.2013.11.016

Poynard, Thierry ; Vergniol, Julien ; Ngo, Yen ; Foucher, Juliette ; Munteanu, Mona ; Merrouche, Wassil ; Colombo, Massimo ; Thibault, Vincent ; Schiff, Eugene ; Brass, Clifford A. ; Albrecht, Janice K. ; Rudler, Marika ; Deckmyn, Olivier ; Lebray, Pascal ; Thabut, Dominique ; Ratziu, Vlad ; De Ledinghen, Victor. / Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). In: Journal of Hepatology. 2014 ; Vol. 60, No. 4. pp. 706-714.

@article{9ac0973e6fc249f6915396e6d235c6f2,

title = "Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest{\texttrademark}) and transient elastography (FibroScan{\textregistered})",

abstract = "Background & Aims FibroTest{\texttrademark} (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called {"}EPIC{"}, {"}Paris{"}, and {"}Bordeaux{"} cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p ",

keywords = "Cirrhosis complications, Elastography, Fibrosis stages, FibroTest{\texttrademark}, Hepatocellular carcinoma, Prognostic factors, Surrogate markers",

author = "Thierry Poynard and Julien Vergniol and Yen Ngo and Juliette Foucher and Mona Munteanu and Wassil Merrouche and Massimo Colombo and Vincent Thibault and Eugene Schiff and Brass, {Clifford A.} and Albrecht, {Janice K.} and Marika Rudler and Olivier Deckmyn and Pascal Lebray and Dominique Thabut and Vlad Ratziu and {De Ledinghen}, Victor",

year = "2014",

doi = "10.1016/j.jhep.2013.11.016",

language = "English",

volume = "60",

pages = "706--714",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

AU - Poynard, Thierry

AU - Vergniol, Julien

AU - Ngo, Yen

AU - Foucher, Juliette

AU - Munteanu, Mona

AU - Merrouche, Wassil

AU - Colombo, Massimo

AU - Thibault, Vincent

AU - Schiff, Eugene

AU - Brass, Clifford A.

AU - Albrecht, Janice K.

AU - Rudler, Marika

AU - Deckmyn, Olivier

AU - Lebray, Pascal

AU - Thabut, Dominique

AU - Ratziu, Vlad

AU - De Ledinghen, Victor

PY - 2014

Y1 - 2014

N2 - Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called "EPIC", "Paris", and "Bordeaux" cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p

AB - Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called "EPIC", "Paris", and "Bordeaux" cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p

KW - Cirrhosis complications

KW - Elastography

KW - Fibrosis stages

KW - FibroTest™

KW - Hepatocellular carcinoma

KW - Prognostic factors

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=84896392780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896392780&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2013.11.016

DO - 10.1016/j.jhep.2013.11.016

M3 - Article

C2 - 24291240

AN - SCOPUS:84896392780

VL - 60

SP - 706

EP - 714

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 4

ER -